Braveheart Bio (NASDAQ:BRVE) Major Shareholder Bio Fund Iv L.P. Ah Buys 1,100,000 Shares of Stock

Braveheart Bio, Inc. (NASDAQ:BRVE) major shareholder Bio Fund Iv L.P. Ah acquired 1,100,000 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The stock was acquired at an average price of $18.00 per share, for a total transaction of $19,800,000.00. Following the completion of the acquisition, the insider directly owned 10,232,420 shares of the company’s stock, valued at $184,183,560. The trade was a 12.05% increase in their position. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Braveheart Bio Price Performance

BRVE stock traded down $2.52 during midday trading on Tuesday, hitting $25.01. 724,651 shares of the company’s stock were exchanged, compared to its average volume of 569,084. Braveheart Bio, Inc. has a 1-year low of $24.61 and a 1-year high of $32.00.

About Braveheart Bio

We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (“HCM”) and other serious cardiovascular diseases. Our lead product candidate, BHB‑1893, is a next-generation oral small‑molecule cardiac myosin inhibitor (“CMI”), that we are developing for the treatment of obstructive HCM (“oHCM”) and non‑obstructive HCM (“nHCM”). Our goal is to improve the treatment options for these patients by enhancing speed of onset, depth of gradient response, systolic safety, and reversibility, and reducing prescribing complexity.